New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
24 Noviembre 2023 - 7:55AM
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare disease of the central
nervous system, has initiated a clinical trial using its
proprietary therapy, SCI-210, at Soroka Medical Center, Israel,
targeting Autism Spectrum Disorder (ASD) symptoms in children.
SciSparc’s novel SCI-210 therapy is not only a medication based
on CBD; it is also a unique combination of cannabidiol (CBD) and
SciSparc's proprietary Palmitoylethanolamide, aimed to ease the
symptoms of ASD.
How will it work?
Over a period of 20 weeks, the trial will enroll 60 participants
between the ages of 5-18 years old to scientifically measure how
SCI-210 compares to standard CBD treatment in managing ASD
symptoms. The trial is structured as a randomized, double-blind,
placebo-controlled trial, which is the gold standard for clinical
research.
Oz Adler, SciSparc's Chief Executive Officer, stated, "Our
pioneering treatment aims to reduce and alleviate the symptoms of
autism along with reducing the side effects that are common when
taking cannabis-based treatments, such as CBD. Partnering with the
Soroka Medical Center and the National Autism Research Center, we
are exploring new territory in ASD treatment. We are driven by
science and the goal of improving life quality for children with
ASD and their families."
The spectrum of ASD is as diverse as the individuals it affects,
challenging social interaction and communication. SciSparc's bold
initiative aims to offer a brighter, more connected future for
those on the autism spectrum.
About SciSparc Ltd. (Nasdaq:
SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive CBD: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer's disease and agitation;
SCI-160 for the treatment of pain; and SCI-210 for the treatment of
ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp
seeds’ oil-based products on
the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses: the goals and objectives of the
SCI-210 clinical trial and the Company’s optimism that SCI-210
could be a pioneering ASD treatment. Because such statements deal
with future events and are based on SciSparc's current
expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of SciSparc could
differ materially from those described in or implied by the
statements in this press release. The forward-looking statements
contained or implied in this press release are subject to other
risks and uncertainties, including those discussed under the
heading "Risk Factors" in SciSparc's Annual Report on Form 20-F
filed with the SEC on May 1, 2023, and in subsequent filings
with the U.S. Securities and Exchange Commission. Except as
otherwise required by law, SciSparc disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Investor Contact: IR@scisparc.com Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024